Neuroone Medical Technologies Corp (NMTC)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $6.78M
Last updated: Nov 17, 2026 at 11:00 AM ET
Neuroone Medical Technologies Corp (NMTC) Earnings: Report Dates and Results
Neuroone Medical Technologies (NMTC) is confirmed to report earnings on Dec 15, 2026, after the close. In the quarter ended Jun 30, 2026, Neuroone Medical Technologies reported EPS of -$0.28, below the -$0.22 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
NMTC has a confirmed report date of Dec 15, 2026, after the close.
NMTC Earnings Call
The latest NMTC earnings call transcript on file is labeled 2026Q2.
Read the 2026Q2 transcriptEarnings History
Of the 21 quarters below that had an estimate, NMTC beat 11, missed 6 and matched 4. Revenue for the quarter ended Jun 30, 2026 was $1.97M, up 15.9% from $1.70M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | -$0.28 | -$0.22 | -$0.26 - -$0.17 | -27.27% | Miss | N/A | 3 | 1 up, 0 down | Aug 13, 2026 | $1.97M |
| Mar 31, 2026 | -$0.25 | -$0.23 | -$0.30 - -$0.14 | -8.43% | Miss | N/A | 3 | 1 up, 1 down | May 12, 2026 | $2.39M |
| Dec 31, 2025 | -$0.18 | -$0.24 | -$0.24 - -$0.18 | +25.00% | Beat | -150.0% | 2 | 0 up, 0 down | Feb 17, 2026 | $2.89M |
| Sep 30, 2025 | -$0.03 | -$0.06 | N/A | +46.00% | Beat | N/A | 2 | 0 up, 1 down | Dec 17, 2025 | $2.74M |
| Jun 30, 2025 | -$0.18 | -$0.30 | N/A | +40.00% | Beat | N/A | N/A | 0 up, 0 down | Aug 14, 2025 | $1.70M |
| Mar 31, 2025 | -$0.42 | -$0.54 | N/A | +22.22% | Beat | N/A | N/A | 0 up, 0 down | May 13, 2025 | $1.39M |
| Dec 31, 2024 | $0.36 | -$0.60 | N/A | +160.00% | Beat | N/A | N/A | 0 up, 1 down | Feb 12, 2025 | $3.27M |
| Sep 30, 2024 | -$0.11 | -$0.09 | N/A | -24.44% | Miss | N/A | N/A | N/A | Dec 17, 2024 | $272284 |
| Jun 30, 2024 | -$0.10 | -$0.09 | N/A | -12.44% | Miss | N/A | N/A | 1 up, 1 down | Aug 14, 2024 | $825776 |
| Mar 31, 2024 | -$0.11 | -$0.10 | N/A | -10.20% | Miss | N/A | N/A | 1 up, 1 down | May 14, 2024 | $1.38M |
| Dec 31, 2023 | -$0.84 | -$0.84 | -$0.84 - -$0.84 | 0.00% | In line | N/A | 2 | 0 up, 0 down | Feb 13, 2024 | $977649 |
| Sep 30, 2023 | -$0.13 | -$0.17 | -$0.18 - -$0.17 | +23.53% | Beat | N/A | 2 | 0 up, 0 down | Dec 14, 2023 | $741780 |
| Jun 30, 2023 | -$1.20 | -$1.23 | -$1.26 - -$1.20 | +2.44% | Beat | N/A | 2 | 0 up, 0 down | Aug 14, 2023 | $629906 |
| Mar 31, 2023 | -$1.26 | -$1.23 | -$1.26 - -$1.20 | -2.44% | Miss | N/A | 2 | 0 up, 0 down | May 11, 2023 | $466176 |
| Dec 31, 2022 | -$0.66 | -$0.66 | -$0.66 - -$0.66 | 0.00% | In line | N/A | 1 | 0 up, 0 down | Feb 13, 2023 | $114579 |
| Sep 30, 2022 | -$0.09 | -$0.11 | -$0.23 - $0.01 | +18.18% | Beat | N/A | 2 | 0 up, 0 down | Dec 22, 2022 | $68788 |
| Jun 30, 2022 | -$1.02 | -$1.35 | -$1.44 - -$1.26 | +24.44% | Beat | N/A | 2 | 0 up, 0 down | Aug 11, 2022 | $32049 |
| Mar 31, 2022 | -$1.14 | -$1.20 | -$1.26 - -$1.14 | +5.00% | Beat | N/A | 2 | 0 up, 0 down | May 12, 2022 | $36584 |
| Dec 31, 2021 | -$1.08 | -$1.14 | -$1.14 - -$1.08 | +5.26% | Beat | N/A | 2 | 0 up, 0 down | Feb 14, 2022 | $33748 |
| Sep 30, 2021 | -$0.22 | -$0.22 | -$0.25 - -$0.22 | 0.00% | In line | N/A | 2 | 0 up, 0 down | Dec 15, 2021 | $48336 |
| Jun 30, 2021 | -$0.25 | -$0.25 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 13, 2021 | $40096 |
| Mar 31, 2021 | -$0.64 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 14, 2021 | $18240 |
| Dec 31, 2020 | -$0.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Feb 16, 2021 | $71474 |
| Sep 30, 2020 | -$0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 8, 2020 | $1.93M |
| Jun 30, 2020 | -$0.44 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 13, 2020 | N/A |
| Mar 31, 2020 | -$0.10 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 14, 2020 | N/A |
| Dec 31, 2019 | -$0.34 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jan 28, 2020 | N/A |
| Sep 30, 2019 | -$0.10 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 20, 2019 | N/A |
| Jun 30, 2019 | -$0.14 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 14, 2019 | N/A |
| Mar 31, 2019 | -$0.20 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 10, 2019 | N/A |
| Dec 31, 2018 | -$0.14 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Feb 14, 2019 | N/A |
| Sep 30, 2018 | -$0.25 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 12, 2018 | N/A |
| Jun 30, 2018 | -$0.16 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 13, 2018 | N/A |
| Mar 31, 2018 | -$0.17 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 16, 2018 | N/A |
| Dec 31, 2017 | -$0.52 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2018 | N/A |
| Sep 30, 2017 | -$0.63 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2017 | N/A |
| Jun 30, 2017 | -$0.56 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 14, 2017 | N/A |
| Mar 31, 2017 | -$0.66 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 17, 2017 | N/A |
| Dec 31, 2016 | -$0.42 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2017 | N/A |
| Sep 30, 2016 | -$0.14 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 21, 2016 | N/A |
Annual EPS
EPS for the fiscal year ended Sep 30, 2026 was -$0.71, after -$0.27 the year before. It was -$2.27 for the year ended Sep 30, 2017, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Sep 30, 2026 | -$0.71 | N/A |
| Sep 30, 2025 | -$0.27 | N/A |
| Sep 30, 2024 | -$1.16 | N/A |
| Sep 30, 2023 | -$3.25 | N/A |
| Sep 30, 2022 | -$3.33 | N/A |
| Sep 30, 2021 | -$1.20 | N/A |
| Sep 30, 2020 | -$0.91 | N/A |
| Sep 30, 2019 | -$0.58 | N/A |
| Sep 30, 2018 | -$1.10 | N/A |
| Sep 30, 2017 | -$2.27 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 3,500 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q2 | Jun 30, 2026 | 3,539 | 6 | |
| 2026Q1 | Mar 31, 2026 | 2,762 | 5 | |
| 2025Q4 | Dec 31, 2025 | 4,484 | 5 | |
| 2025Q3 | Sep 30, 2025 | 2,490 | 4 | |
| 2025Q2 | Jun 30, 2025 | 2,685 | 5 | |
| 2025Q1 | Mar 31, 2025 | 2,602 | 4 | |
| 2024Q4 | Dec 31, 2024 | 1,926 | 3 | |
| 2024Q3 | Sep 30, 2024 | 1,463 | 3 |
2026Q2 Earnings Call
Opening remarks
David Rosa Chief Executive Officer Thank you, operator, and thank you to everyone for joining us today. I'd like to welcome you to our second quarter fiscal 2026 financial results conference call. Product revenue for the OneRF brain ablation system in the second quarter of fiscal 2026 grew 72% year-over-year to $2.4 million compared to $1.4 million in the second quarter of fiscal 2025. We continue to be energized by reports of the positive impact this therapy is having on people's lives. Most recently, the U.S. Department of Veterans Affairs published an article regarding Dr. Garrett Banks' experience with the technology. The article discussed the challenges that Navy veteran Derek Harpole had to endure after being diagnosed with epilepsy. For more than two decades, he was unable to work, drive or hunt alone. Dr. Banks and his team at the Houston VA performed their first OneRF brain ablation procedure on Derek. He woke up the morning after the procedure "bright-eyed and bushy-tailed," in his words. With his seizures dramatically reduced, he now has hope that he can regain the life he once had. Through our partnership with Zimmer Biomet, our goal is to expand this therapy into new centers in order to change other people's lives as well. The company also had several important corporate developments I'd like to highlight. First, we appointed David Wambeke as Chief Business Officer to lead our drug delivery program, oversee Investor Relations and support business development. As a meaningful sign of his confidence, David purchased 1 million shares of NeuroOne common stock on a pre-split basis. We were also pleased to announce that we regained compliance with NASDAQ's minimum bid price requirement following a 1-for-6 reverse split of our common stock. Finally, we are always excited to welcome new investors, and we're pleased to learn a new high net worth investor acquired approximately 7.4% of our outstanding common stock in the open market. Now let's move on to discuss the exciting progress we have made with our existing product portfolio. Regarding our OneRF brain ablation system, as I mentioned in the opening, we experienced 72% year-over-year revenue growth. We believe there is upside for growth domestically and internationally. Domestically, we are developing a webinar that will highlight clinical experience with the device that we can expand exposure to neurologists and neurosurgeons that may not be aware of the exciting results that are being reported. With respect to international commercialization progress, we completed the Stage 2 audit of our Minnesota facility for ISO 13485 certification and remain bullish on certification in the latter part of 2026, which is a key step in the process of enabling international distribution of our products.
Frequently Asked Questions About NMTC
When is Neuroone Medical Technologies's next earnings date?
Neuroone Medical Technologies's next earnings report is confirmed for Dec 15, 2026, after the close.
Did NMTC beat earnings estimates last quarter?
No. Neuroone Medical Technologies reported EPS of -$0.28 for the quarter ended Jun 30, 2026, below the -$0.22 estimate by 27.27%.
What EPS do analysts expect from NMTC next quarter?
The consensus EPS estimate for Neuroone Medical Technologies for the quarter ended Sep 30, 2026 is -$0.20 from 5 analysts, with estimates from -$0.20 to -$0.20.
How often does NMTC beat earnings estimates?
Neuroone Medical Technologies beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +29.13%.
Does NMTC report before or after the market opens?
Neuroone Medical Technologies is confirmed to report on Dec 15, 2026, after the market closes.
NMTC pages: Overview, Earnings, Forecast, Financials, Competitors